Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Involvement of CYP3A in the Metabolism of Eplerenone in Humans and Dogs: Differential Metabolism by CYP3A4 and CYP3A5

Chyung S. Cook, Loren M. Berry, David H. Kim, Earl G. Burton, Jeremy D. Hribar and Liming Zhang
Drug Metabolism and Disposition December 2002, 30 (12) 1344-1351; DOI: https://doi.org/10.1124/dmd.30.12.1344
Chyung S. Cook
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Loren M. Berry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David H. Kim
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Earl G. Burton
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy D. Hribar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liming Zhang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In vitro studies were conducted to identify the major metabolites of eplerenone (EP) and the cytochrome P450 (P450) isozymes involved in its primary oxidative metabolism in humans and dogs. The major in vitro metabolites were identified as 6β-hydroxy EP and 21-hydroxy EP in both humans and dogs. EP was metabolized by cDNA-expressed human CYP3A4 and dog CYP3A12 but only minimally by human CYP3A5. In human microsomes, inhibition of total metabolism by the CYP3A-selective inhibitors ketoconazole, troleandomycin, and 6′,7′-dihydroxybergamottin, each at 10 μM concentration, was 83 to 95%, whereas inhibition with inhibitors selective for other P450 isozymes was minimal. In dog liver microsomes, the percentages of inhibition were 53 to 76% with the CYP3A-selective inhibitors. A monoclonal anti-CYP3A4 antibody inhibited EP metabolism by 84%, whereas other monoclonal antibodies had minimal effects. The formation of 6β-hydroxy and 21-hydroxy metabolites in human liver microsomes was best correlated with CYP3A-selective dextromethorphanN-demethylation and testosterone 6β-hydroxylation activities. EP moderately inhibited only CYP3A (testosterone 6β-hydroxylase) activity in human liver microsomes by 23, 34 and 45% at concentrations of 30, 100, and 300 μM, respectively. With human microsomes, the Vmax andKm for 6β-hydroxylation and 21-hydroxylation were 0.973 nmol/min/mg and 217 μM, and 0.143 nmol/min/mg and 211 μM, respectively. The human hepatic clearance calculated from total in vitro EP metabolism was 2.30 ml/min/kg, which agrees with in vivo data. In conclusion, 6β- and 21-hydroxylation of EP is primarily catalyzed by CYP3A4 in humans and CYP3A12 in dogs. Also, it is unlikely that EP would substantially inhibit the metabolism of other drugs that are metabolized by CYP3A4 or other P450 isoforms.

Footnotes

  • Supported by Pharmacia Corporation.

  • Abbreviations used are::
    ACE
    angiotensin-converting enzyme
    EP
    eplerenone
    P450
    cytochrome P450
    LC
    liquid chromatography
    MS
    mass spectometry
    HPLRC
    high-performance liquid radiochromatography
    CLint
    intrinsic clearance
    CLH
    hepatic clearance
    QH
    hepatic blood flow
    fu
    fraction unbound in plasma
    HPLC
    high performance liquid chromatography
    • Received May 14, 2002.
    • Accepted August 26, 2002.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 30 (12)
Drug Metabolism and Disposition
Vol. 30, Issue 12
1 Dec 2002
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Involvement of CYP3A in the Metabolism of Eplerenone in Humans and Dogs: Differential Metabolism by CYP3A4 and CYP3A5
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Involvement of CYP3A in the Metabolism of Eplerenone in Humans and Dogs: Differential Metabolism by CYP3A4 and CYP3A5

Chyung S. Cook, Loren M. Berry, David H. Kim, Earl G. Burton, Jeremy D. Hribar and Liming Zhang
Drug Metabolism and Disposition December 1, 2002, 30 (12) 1344-1351; DOI: https://doi.org/10.1124/dmd.30.12.1344

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Involvement of CYP3A in the Metabolism of Eplerenone in Humans and Dogs: Differential Metabolism by CYP3A4 and CYP3A5

Chyung S. Cook, Loren M. Berry, David H. Kim, Earl G. Burton, Jeremy D. Hribar and Liming Zhang
Drug Metabolism and Disposition December 1, 2002, 30 (12) 1344-1351; DOI: https://doi.org/10.1124/dmd.30.12.1344
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Cytochrome P450 4F11 in lung cancer
  • SLC49A4-mediated pyrilamine transport
  • Functional Characterization of 29 CYP4F2 Variants
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics